Forte Minerals Corp said it is expanding its board of directors to five members with the appointment of Richard Leveille.
According to the company, Leveille has an accomplished career spanning over 40 years, including at companies such as AMAX, Kennecott, Rio Tinto, and Phelps Dodge.
Toubani Resources Inc. (TSX-V:TRE) said it has hired Etasi & Co Drilling SARL to carry out the 2022/23 exploration drilling campaign at its flagship Kobada project in Mali.
ETASI is well placed for the work as it is the successor company to AMCO, which conducted Toubani's phase 1 and 2 programs during the 2019-2022 program.
Maverix Metals Inc (TSX:MMX) has noted that on November 30, 2022, the Ontario Superior Court of Justice (Commercial List) granted an interim order in connection with the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act, under which, among other things and subject to the satisfaction or waiver of all applicable conditions precedent, Triple Flag Precious Metals Corp. will acquire all of the issued and outstanding common shares of Maverix Metals. The interim order authorizes the calling and holding of a special meeting of the Maverix shareholders to be held on January 12, 2023, the granting of dissent rights to the registered Maverix shareholders and other matters relating to the conduct of the special meeting. Maverix said it will provide a further update on the details of the special meeting and how shareholders or their duly appointed proxyholders can attend, access and participate in the special meeting.
Los Andes Copper Ltd (TSX-V:LA) has said that in accordance with the terms of the US$5 million, US$4 million, and US$5 million 8% convertible debentures issued to Queen's Road Capital Investment Ltd on June 2, 2021, April 4, 2022, and Sept. 2, 2022, the company has elected to issue 10,172 common shares in the capital of the company at a deemed price of US$10.28 (C$13.80) to Queen's Road Capital as payment for US$104,568 (C$140,304) in interest owing on the convertible debentures. Under the terms of the convertible debentures, interest is payable quarterly, 5% in cash and 3% in shares, at the greater of: (i) the 20-day volume weighted average price prior to the interest payment date; or (ii) the Discounted Market Price, as such term is defined in the policies of the TSX Venture Exchange (TSX-V). The issuance of the common shares as payment for interest owing on the convertible debentures is subject to the terms and conditions of the convertible debentures as well as the receipt of all requisite approvals, including, without limitation, the approval of the TSX-V.
Iris Energy Limited (NASDAQ:IREN) has announced that it will provide an update in respect of its current positioning, go-forward opportunities and strategic priorities on Tuesday December 6, 2022 Eastern Time, after the market close. Iris Energy will host a conference call to discuss its strategic priorities including time for Q&A beginning at 5.00pm Eastern Time (2.22pm Pacific Time/Wednesday December 7 at 9.00am Australian Eastern Daylight Time). Registration Links: Live Webcast https://onlinexperiences.com/Launch/QReg/ShowUUID=1688A8D8-DC1A-4D88-8297-C0A374C609DF; Phone Dial-In with Live Q&A https://s1.c-conf.com/diamondpass/10027397-gs6etd.html. The webcast will be recorded, and the replay will be accessible shortly after the event at https://investors.irisenergy.co/events-and-presentations.
Genprex, Inc. (NASDAQ:GNPX) announced that its executive vice president, general counsel and chief strategy officer, Catherine Vaczy, will be providing an overview of the company's gene therapies for cancer and diabetes at the RHK 2022 Disruptive Growth Conference in December 2022. The presentation will take place on Tuesday, Dec. 6, at 2:40 p.m. ET. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors.
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from its Small Cap Growth Virtual Investor Conference held on December 1st are now available for online viewing at https://bit.ly/3H26Z7H. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.
AIM ImmunoTech Inc (NYSE:AIM) announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK. Details for the presentation are as follows: Poster No: P-220; Title:Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects; Presenter: Lisanne C.A. Smidt - Centre for Human Drug Research, Leiden, the Netherlands; Session: Poster Session 2; Date & Time: Wednesday December 7, 2022 from 5:30-7:00 PM GMT.